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Abstract
Background—Amplification based HIV-1 viral load and genotypic resistance assays are
expensive, technologically complex and may be difficult to implement in resource limited settings.
Inexpensive, simpler assays are urgently needed.
Objectives—To determine the suitability of the ExaVir™ Load and ExaVir™ Drug assays for use
in patient monitoring.
Study Design—Specimens from 108 adults were used to compare ExaVir™ Load HIV-1 RT to
Amplicor HIV-1 Monitor® HIV-1 RNA, and ExaVir™ Drug phenotype to HIV GenoSure™
genotype.
Results—HIV-1 RT and HIV-1 RNA levels were comparable (Pearson correlation coefficient
0.83). Most (94%) had detectable results in both assays. The mean difference (HIV-1 RT minus
HIV-1 RNA) was -0.21 log10 cps/mL equivalents. Relationship between HIV-1 RT and HIV-1 RNA
was not affected by RT mutations, CD4 cell count, or efavirenz (EFV) or nevirapine (NVP) use.
Phenotypes were generally consistent with genotype findings for EFV, but not for NVP. Most patients
(93.9%) with phenotypic EFV resistance had at least one EFV mutation, while 78.0% of patients
with phenotypic NVP resistance had at least one NVP mutation. Eleven of 49 samples tested for EFV
susceptibility were found resistant (n=2) or with reduced susceptibility (n=9) despite the absence of
genotypic resistance. Eleven of 45 samples tested for NVP susceptibility were found resistant (n=9)
or with reduced susceptibility (n=2) with no evidence of genotypic mutations.
Conclusions—The ExaVir™ Load assay performed well and may be an alternative to
amplification based techniques for HIV-1 RNA quantification. The ExaVir™ Drug assay for
phenotypic resistance testing requires further evaluation, especially for NVP.
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Background
Access to antiretroviral drugs is rapidly expanding around the globe; however, issues of cost
and complexity have limited access to monitoring tools such as HIV-1 viral loads, CD4 cell
counts, and genotypic and phenotypic resistance assays.1 Prompt detection of virologic failure
is essential for preventing further evolution of antiretroviral drug resistant HIV isolates and
preserving future treatment options.2, 3 High rates of antiretroviral drug resistance emerging
on therapy have already been documented in countries with antiretroviral availability but
without available laboratory monitoring.4-7 Inexpensive, technologically simpler assays are
therefore urgently needed.
Objectives
One lower cost, technologically simpler assay is the ExaVir™ Load assay which measures the
reverse transcriptase (RT) activity in plasma.8, 9 Once the RT enzyme has been isolated and
quantitated, its ability to function in the presence of non-nucleoside RT inhibitors and
thymidine analog nucleoside RT inhibitors can also be determined, thereby measuring
susceptibility or resistance of the virus to certain antiretroviral drugs. We evaluated the
performance characteristics of the ExaVir™ Load and ExaVir™ Drug assays and compared
these assay results to those of HIV-1 RNA RT-PCR quantitation and HIV-1 sequencing
analysis, respectively to determine the suitability of these assays for use in patient monitoring
in resource limited settings.
Study Design
HIV-1 Viral Load Assays
The ExaVir™ Load assay, version 2.0 (Cavidi Tech AB, Uppsala, Sweden) was performed,
following manufacturers' package inserts, on EDTA plasma stored at -80°C and frozen/thawed
once, from a random sample of adults with clade B HIV-1, participating in the UNC CFAR
HIV Clinical Cohort Study (n=108).10 Patient samples were eligible to be randomly selected
if a sample was available on a day where: (1) an HIV-1 RNA was performed and was greater
than 1000 cps/mL; and (2) an HIV-1 genotype was also performed. Results were reported as
fentograms RT per milliliter (fg/mL) and converted to HIV-1 RNA copies per milliliter
equivalents (cps/mL eqs) using the ExaVir™ Load Analyzer version 1.62 These results were
compared to HIV RNA levels (Amplicor HIV-1 Monitor® Test, version 1.5, Roche
Diagnostics, Branchburg, NJ, USA).
HIV Drug Resistance Assays
The ExaVir™ Drug assay (ExaVir™ Drug assay, version 1.0, Cavidi Tech AB, Uppsala,
Sweden) 11 was used to test for phenotypic resistance to efavirenz (EFV) (n=48), nevirapine
(NVP) (n=37), and both EFV and NVP (n=23). The percentage of inhibition was calculated
for each drug concentration as the ratio of HIV-1 RT activity with drug present to HIV-1 RT
activity with drug absent (×100). Samples were considered resistant if the sample half maximal
inhibitory concentration (IC50) was ≥ the IC50 of the mutant referent, susceptible if the sample
IC50 was < 2 times the IC50 of the wild type referent, and with reduced susceptibility otherwise,
based on the assay provided software. The manufacturer recommends a minimum 10 fg/ml RT
level for phenotypic drug susceptibility testing which is approximately 4000 cps/ml eqs (3.6
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log cps/ml eqs). These phenotypic results were compared to HIV-1 genotyping (HIV
GenoSure™, LabCorp, Research Triangle Park, NC, USA).
Statistical Analysis
HIV-1 RNA and HIV-1 RT levels were log10 transformed, and results less than the assay limit
of detection were imputed at half the lower limit. Log10 HIV-1 RT level (cps/mL eqs) assay
values were compared to the log10 HIV-1 RNA level (cps/mL) assay values via descriptive
statistical methods, Bland-Altman analysis of agreement, Pearson's correlation coefficient (r),
and linear regression methods. Multivariable linear regression was used to investigate whether
the differences between HIV-1 RT and HIV-1 RNA were affected by: (1) current or prior use
of EFV and NVP; (2) cumulative number of RT mutations; (3) specific RT mutation; and (4)
contemporaneous CD4 cell count. The following RT mutations were considered based on the
International AIDS Society – USA Panel Guidelines12: M41L, A62V, K65R, D67N, T69Insert,
K70R, L74V, V75I, F77L, Y115F, F116Y, Q151M, M184I/V, L210W, T215F/Y, and K219E/
Q; including the following EFV and/or NVP related mutations: L100I, K103N, V106A/M,
V108I, Y181C/I, Y188C/L/H, G190A/S, and P225H. All statistical computations were
performed using SAS software (version 9.1, SAS Institute, Inc., Cary, NC).
Results
Plasma samples from 108 individuals with HIV-1 RNA levels >1000 cps/mL were used to
compare HIV-1 RT and HIV-1 RNA assay results. Most (N=102) had detectable results in both
assays, and 94 had quantifiable HIV-1 RT and HIV-1 RNA (Figure 1A). Eight samples gave
measurable HIV-1 RT but HIV-1 RNA was above the assay linear range (i.e., >5.88 log10 cps/
mL; median HIV-1 RT=5.71 log10 cps/mL eqs (Interquartile range [IQR]; 5.06, 5.73). In six
samples HIV-1 RT was below assay limit of detection but HIV-1 RNA result was measurable
(median HIV-1 RNA=3.60 log10 cps/mL (IQR; 3.45, 4.06).
The difference between the two assays was within 0.3, 0.5 and 1.0 log10 cps/mL eqs in 53.2%,
75.5% and 92.6% of samples with results on both assays (N=94), respectively. When the HIV-1
RNA result was >1000, >5000 or >10,000 cps/mL, 102 of 108 (94.4%), 82 of 84 (97.6%), and
64 of 66 (97.0%) had quantifiable HIV-1 RT results, respectively.
The means of the HIV-1 RT and HIV-1 RNA assays were 4.26 and 4.47 log10 cps/mL
(SD=1.04, 0.86); and the medians were 4.15 and 4.30 log10 cps/mL eqs (IQR; 3.52, 5.21; 3.78,
5.13), respectively. The mean difference (HIV-1 RT minus HIV-1 RNA) was -0.21 log10 cps/
mL eqs (SD=0.59) [lower and upper 95% limits of agreement=-1.36 (95% Confidence Interval
[CI]; -1.55, -1.17), and 0.94 (95% CI; 0.75, 1.13)], and did not appear to be influenced by the
amount of virus present (Figure 1B). The Pearson's correlation coefficient was r=0.83 [0.76,
0.88].
The difference between HIV-1 RT and HIV-1 RNA was not appreciably affected by current
NNRTI (N=27), EFV (N=16), or NVP use (N=11), or prior/never NNRTI use (N=53), with
mean differences of: -0.37 log10 cps/mL eqs (SD=0.49), -0.43 (SD=0.55), -0.27 (SD=0.40),
and -0.16 (SD=0.61), respectively. All contrasts of the mean differences by NNRTI use had
likelihood ratio test p-values > 0.10.).
Of the 108 patients, 83 had virus with ≥1 RT, 65 with ≥1 EFV or NVP, and 69 with ≥1 NRTI
mutation. The median number of RT mutations was 3 (IQR; 1, 5). The most common mutations
were M184V (N=49), K103N (N=39), T215Y (N=33), M41L (N=32), and Y181C (N=27). In
multivariable analyses neither the number of RT, EFV or NVP mutations, nor any specific
mutation, affected the relationship between HIV-1 RT and HIV-1 RNA. Current CD4 cell
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count also did not appear to affect the difference between HIV-1 RT and HIV-1 RNA (p-
value=0.35).
Phenotypic drug susceptibility was undertaken for EFV (N=71) and NVP (N=60), but was
unmeasurable due to low HIV-1 RT levels (< 10 fg RT/ml) in 22 (31%) EFV and 15 (25%)
NVP attempts. The median HIV-1 RT and HIV-1 RNA levels in these 37 unmeasurable
samples were 3.13 and 3.76 log10 cps/mL eqs (IQR; 2.79, 3.65; 3.45, 4.08), respectively.
Of the 49 available EFV phenotypes, 33 were resistant, 12 had reduced susceptibility, and 4
were susceptible. Of the EFV resistant patients (N=33), all 16 with NVP phenotype data were
also NVP resistant. Among the 12 patients with EFV reduced susceptibility, 7 had available
NVP data and 4 were NVP resistant, 1 had NVP reduced susceptibility and 2 were NVP
susceptible. None of the EFV susceptible patients had available NVP phenotypes.
In general EFV phenotype resistance findings were consistent with RT genotype results (Figure
2). Of 33 patients with phenotypes indicating EFV resistance, 31 had ≥1 EFV associated
mutation. No EFV mutations were observed in patients with phenotypes indicating EFV
susceptibility (N=4). However, of the 12 patients with phenotypic results indicating reduced
EFV susceptibility, 9 had no evidence of EFV mutations, and 5 had never received EFV or
NVP.
Of the 45 NVP phenotypes, 41 were resistant, 2 had reduced susceptibility, and 2 were
susceptible (Figure 2). Nine of 41 patients with phenotypes indicating NVP resistance, and all
with NVP reduced susceptibility, had no evidence of NVP mutations, or any RT mutations,
including an expanded list of NNRTI mutations including etravirine associated mutations. Of
these eleven patients with NVP resistance or reduced susceptibility but without corresponding
NVP mutations only one had any history of EFV or NVP use.
Discussion
The required technology and equipment used in the ExaVir™ Load assay are relatively simple
and inexpensive, and the output of HIV-1 RNA cps/mL equivalents offers a surrogate for HIV-1
RNA values readily interpretable to clinicians. The RT extract may also be used to obtain a
susceptibility phenotype to NNRTI and thymidine analogue NRTI antiretroviral drugs, a
potentially low cost alternative to genotyping.11
Our findings contrasting the ExaVir™ Load assay to HIV-1 RNA RT-PCR quantitation
(Amplicor HIV-1 Monitor® Test) confirm prior work indicating that HIV-1 RT and HIV-1
RNA results, in general, are comparable. Our observed mean difference (HIV-1 RT minus
HIV-1 RNA) of -0.21 log10 cps/mL (eqs), was similar to results from a cohort of patients
predominantly infected with non-clade B HIV-1 virus (mean difference -0.23 log10 cps/mL
[eqs].13
The Pearson correlation coefficient in this study (r=0.83, CI=[0.76, 0.88]), was only slightly
lower than those reported in prior studies (ranging from r=0.85 to r=0.90).8, 9, 14-21 Although
the majority of studies have not observed differences in assay performance comparing clade
B and non-clade B populations,14 a few studies have reported weaker correlation coefficients
(r=0.65 to r=0.81) in samples from patients with non-clade B HIV-1 virus.17, 22, 23
Among samples with HIV-1 RNA greater than 1000 cps/mL, 94% had quantifiable HIV-1 RT
results. When a higher HIV-1 RNA cut-off was used a slightly greater proportion of samples
also had quantifiable HIV-1 RT results (e.g., 97% of samples with HIV-1 RNA greater than
10,000 cps/mL). This observation may be clinically relevant as more complex resistance
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patterns are seen in patients in resource limited settings failing initial therapy with viral loads
greater than 10,000 cps/mL.7, 24
The binding mode of inhibition of EFV to RT is known to be much tighter than that of NRTIs
or the other NNRTIs,25 raising the possibility of HIV-1 RT suppression by the presence of
EFV in the sample. A prior study did not find a difference by EFV exposure, with correlation
coefficients for HIV-1 RT and HIV-1 RNA among EFV users and non-users of 0.86 and 0.89,
respectively.15 In this study the correlation coefficients for current and never/prior EFV users
were 0.83 and 0.87, respectively. In additional analyses contrasting the mean differences
(HIV-1 RT minus HIV-1 RNA) by EFV use, differences were not statistically significant.
Given the available data it appears that current EFV use has a small and possibly negligible
effect on the performance of the HIV-1 RT.
Greengrass and colleagues, observed an effect of NNRTI resistance mutations on the
relationship between HIV-1 RT and HIV-1 RNA suggesting a possible decrease in RT fitness.
15 Using the same analytic approach we did not find evidence that the presence of at least one
EFV or NVP mutation affected the association between HIV-1 RT and HIV-1 RNA.
Only 70-75% of the samples had sufficient RT levels to perform the phenotypic assays. The
EFV phenotype assay worked fairly well. Only 6% of samples determined to be phenotypically
resistant to EFV did not harbor EFV associated mutations, and all of the samples determined
to be phenotypically susceptible had wild type RT. However, only 25% of samples determined
to have phenotypic reduced susceptibility had detectable EFV mutations. These results are in
contrast to those of Basson, et al.,26 who found that only 6.5% of subtype C specimens
demonstrated phenotypic resistance in the absence of genotypic mutations. All of the
specimens we tested were subtype B. Since the phenotypic reduced susceptibility category
appears to have substantial misclassification problems, the overall assay performance could
be improved by changing the cutoff for determining susceptibility or by only including two
categories (resistant and susceptible).
The phenotypic NVP resistance findings based on the ExaVir™ Drug assay were discordant
in comparison to genotyping results in a large number of patient samples. One-fifth of samples
indicating NVP resistance based on phenotypic drug susceptibility testing had no NVP
associated mutations. These results were not explained by NVP or EFV use, since the majority
of these patients were NNRTI-naïve. Moreover, the majority of these patients did not have
mutations conferring resistance to any NRTI, or to a broader list of NNRTI mutations. While
a small number of discrepant results between a resistant phenotype and an apparently sensitive
genotype could occur due to undetected or unrecognized mutations we believe this is an
unlikely explanation for our observations given the extensive study and characterization of
EFV and NVP resistance over the last 10-15 years.
Single dose NVP is the most common antiretroviral regimen used for the prevention of mother
to child transmission in resource limited settings and resistance frequently develops in mothers
and infected infants.27, 28 Therefore, given the findings of this study, the ExaVir™ Drug assay
needs further evaluation, especially for NVP resistance. In addition, the phenotypic assay can
only be performed on NNRTIs and T-analogue NRTIs which limits its utility. On the other
hand, the ExaVir™ Load assay HIV-1 RT appears comparable to HIV-1 RNA based on RT-
PCR quantitation, and is not appreciably affected by NNRTI use or RT mutations.
Acknowledgments
Acknowledgements and Conflicts of Interest
Napravnik et al. Page 5













Funding: This work was supported by National Institute of Allergy and Infectious Diseases (NIAID) grants AI068636
and AI069423 (AIDS Clinical Trials Group Central Grant) and AI068632 [International Maternal Pediatric Adolescent
AIDS Clinical Trials Group (IMPAACT) Central Grant]. IMPAACT is also funded by the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health
(NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views
of the NIAID, NICHD, NIMH, or NIH. This research was also supported by The University of North Carolina at
Chapel Hill, Center for AIDS Research, National Institutes of Health funded program P30 AI50410. Competing
interests: None declared. Ethical approval: This study was approved by the Institutional Review Board of the University
of North Carolina at Chapel Hill.
References
1. Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for resource-limited settings. PLoS
Med 2006;3(10):1743–50.
2. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr. HIV-1 drug resistance evolution
among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune
Defic Syndr 2005;40(1):34–40. [PubMed: 16123679]
3. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in
heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive
treatment regimen. Clin Infect Dis 2006;43(10):1329–36. [PubMed: 17051502]
4. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue
regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20(10):1391–9. [PubMed:
16791013]
5. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need
for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring
in developing countries. J Acquir Immune Defic Syndr 2002;29(2):165–8. [PubMed: 11832686]
6. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-
resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir
Immune Defic Syndr 2001;26(5):501–6. [PubMed: 11391173]
7. Hosseinipour, M.; van Oosterhout, JJ.; Weigel, R., et al. Resistance profile of patients failing first line
ART in Malawi when using clinical and immunologic monitoring. Presented at the XVII International
AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract # TUAB0105
8. Malmsten A, Shao XW, Aperia K, et al. HIV-1 viral load determination based on reverse transcriptase
activity recovered from human plasma. J Med Virol 2003;71(3):347–59. [PubMed: 12966539]
9. Malmsten A, Shao XW, Sjodahl S, et al. Improved HIV-1 viral load determination based on reverse
transcriptase activity recovered from human plasma. J Med Virol 2005;76(3):291–6. [PubMed:
15902697]
10. Napravnik S, Eron JJ, McKaig RG, Heine AD, Menezes P, Quinlivan E. Factors associated with fewer
visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 2006;18(7):
45–50.
11. Shao XW, Malmsten A, Lennerstrand J, et al. Use of HIV-1 reverse transcriptase recovered from
human plasma for phenotypic drug susceptibility testing. AIDS 2003;17(10):1463–71. [PubMed:
12824784]
12. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1:
December 2008. Top HIV Med 2008;16(5):138–45. [PubMed: 19106428]
13. Iqbal HS, Balakrishnan P, Cecelia AJ, et al. Use of an HIV-1 reverse-transcriptase enzyme-activity
assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring
antiretroviral therapy in resource-limited settings. J Med Microbiol 2007;56(Pt 12):1611–4.
[PubMed: 18033828]
14. Braun J, Plantier JC, Hellot MF, et al. A new quantitative HIV load assay based on plasma virion
reverse transcriptase activity for the different types, groups and subtypes. AIDS 2003;17(3):331–6.
[PubMed: 12556686]
15. Greengrass VL, Turnbull SP, Hocking J, et al. Evaluation of a low cost reverse transcriptase assay
for plasma HIV-1 viral load monitoring. Curr HIV Res 2005;3(2):183–90. [PubMed: 15853722]
Napravnik et al. Page 6













16. Steegen K, Luchters S, De Cabooter N, et al. Evaluation of two commercially available alternatives
for HIV-1 viral load testing in resource-limited settings. J Virol Methods 2007;146(12):178–87.
[PubMed: 17686534]
17. Sivapalasingam S, Essajee S, Nyambi PN, et al. Human immunodeficiency virus (HIV) reverse
transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J
Clin Microbiol 2005;43(8):3793–6. [PubMed: 16081912]
18. Jennings C, Fiscus SA, Crowe SM, et al. Comparison of two human immunodeficiency virus (HIV)
RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol 2005;43(12):5950–6.
[PubMed: 16333081]
19. Mine M, Bedi K, Maruta T, et al. Quantitation of human immunodeficiency virus type 1 viral load
in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a
decentralization pilot study. J Virol Methods 2009;159(1):93–7. [PubMed: 19442851]
20. Greengrass VL, Plate MM, Steele PM, et al. Evaluation of the Cavidi ExaVir Load assay (version 3)
for plasma human immunodeficiency virus type 1 load monitoring. J Clin Microbiol 2009;47(9):
3011–3. [PubMed: 19605583]
21. Greengrass V, Lohman B, Morris L, et al. Assessment of the Low-Cost Cavidi ExaVir Load Assay
for Monitoring HIV Viral Load in Pediatric and Adult Patients. J Acquir Immune Defic Syndr. 2009
22. Seyoum E, Wolday D, Girma M, et al. Reverse transcriptase activity for quantitation of HIV-1 subtype
C in plasma: relation to RNA copy number and CD4 T-cell count. J Med Virol 2006;78(2):161–8.
[PubMed: 16372295]
23. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially
available, inexpensive alternative assays used for assessing viral load in a cohort of human
immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol
2005;43(2):857–61. [PubMed: 15695692]
24. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial
regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis
2007;44(3):447–52. [PubMed: 17205457]
25. Motakis D, Parniak MA. A tight-binding mode of inhibition is essential for anti-human
immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.
Antimicrob Agents Chemother 2002;46(6):1851–6. [PubMed: 12019100]
26. Basson AE, Ntsala M, Martinson N, et al. Development of phenotypic HIV-1 drug resistance after
exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2008;49(5):538–43. [PubMed:
18989222]
27. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women
and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS
2001;15(15):1951–7. [PubMed: 11600822]
28. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence
of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants




Cp/mL eqs Copies per milliliter equivalents
EFV Efavirenz
IC50 Half maximal inhibitory concentration
IQR Interquartile range
NNRTI Non-nucleoside reverse transcriptase inhibitor
NRTI Nucleoside reverse transcriptase inhibitor
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ExaVir™ Load assay log10 HIV-1 RT level and Amplicor HIV-1 Monitor® Test log10 HIV-1
RNA level with the line of equality (A). HIV-1 RT and HIV-1 RNA measurable N=94, denoted
by (●); HIV-1 RT measurable and HIV-1 RNA above the linear range of the assay N=8, denoted
by (○); and HIV-1 RT below the linear range of the assay and HIV-1 RNA measurable N=6,
denoted by (*). Bland-Altman difference plot of difference in HIV-1 RT minus HIV-1 RNA
versus average values of HIV-1 RT and HIV-1 RNA, with mean difference and 95% limits of
agreement (B).
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Comparison of the ExaVir™ Drug (phenotype) assay and HIV GenoSure™ (genotype)
mutation results for assessing efavirenz resistance (N=49) and nevirapine resistance (N=45).
The following efavirenz mutations were included: L100I, K103N, V106M, V108I, Y181C/I,
Y188L, and G190A/S; and no patient had V106M or P225H. The following nevirapine
mutations were included: L100I, K103N, V106A/M, V108I, Y181C/I, Y188C/L/H, and
G190A; and no patient had V106M.
NOTE: Non-nucleoside reverse transcriptase inhibitor (NNRTI); efavirenz (EFV); nevirapine
(NVP); Reduced Susceptibility (Red. Suscept.).
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